Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 24, Issue 2, Pages 312-320
Publisher
Wiley
Online
2021-11-02
DOI
10.1111/dom.14583
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
- (2020) Yasuhiro Matsubayashi et al. DIABETES OBESITY & METABOLISM
- Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomised controlled study
- (2019) Zeeshan Javed et al. CLINICAL ENDOCRINOLOGY
- Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study
- (2019) Ruban Dhaliwal et al. DIABETES CARE
- Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial
- (2019) Yujing Li et al. FERTILITY AND STERILITY
- Comparison of gastrointestinal adverse events with different doses of metformin in the treatment of elderly people with type 2 diabetes
- (2019) Huang Yuxin et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review
- (2019) Habib Yaribeygi et al. LIFE SCIENCES
- Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment
- (2018) Héctor F. Escobar-Morreale Nature Reviews Endocrinology
- New perspectives on the definition and management of polycystic ovary syndrome
- (2018) R. Pasquali et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome
- (2018) Liangshan Mu et al. Reproductive Biology and Endocrinology
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial
- (2017) Macarena Alpañés et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins
- (2017) Mina Amiri et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
- (2017) Xiaoling Cai et al. Obesity
- Clinical study on the association between pregnancy-induced hypertension and insulin resistance
- (2017) Zhifang Chen et al. Experimental and Therapeutic Medicine
- SGLT2 inhibitors
- (2016) I. Dardi et al. BIOCHEMICAL PHARMACOLOGY
- Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
- (2016) Manuel Luque-Ramírez et al. CURRENT PHARMACEUTICAL DESIGN
- Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes
- (2016) Julio Rosenstock et al. DIABETES CARE
- Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies
- (2016) Samantha Cassar et al. HUMAN REPRODUCTION
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
- (2015) Norm Rosenthal et al. Annals of the New York Academy of Sciences
- Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
- (2015) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME -PART 2
- (2015) Neil F. Goodman et al. Endocrine Practice
- SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
- (2015) Jochen Seufert Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial
- (2014) A. Esteghamati et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
- (2013) D. Polidori et al. DIABETES CARE
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp
- (2013) N. K. Stepto et al. HUMAN REPRODUCTION
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial
- (2013) Wenying Yang et al. Lancet Diabetes & Endocrinology
- Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
- (2012) S. T. Bird et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
- (2012) Evanthia Diamanti-Kandarakis et al. ENDOCRINE REVIEWS
- Metformin in Obese Children and Adolescents: The MOCA Trial
- (2012) D. Kendall et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Insulin resistance index (HOMA-IR) levels in a general adult population: Curves percentile by gender and age. The EPIRCE study
- (2011) Pilar Gayoso-Diz et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Optimal reference interval for homeostasis model assessment of insulin resistance in a Japanese population
- (2011) Chizumi Yamada et al. Journal of Diabetes Investigation
- Metformin Decreases the Adipokine Vaspin in Overweight Women With Polycystic Ovary Syndrome Concomitant With Improvement in Insulin Sensitivity and a Decrease in Insulin Resistance
- (2008) B. K. Tan et al. DIABETES
- The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials
- (2008) Kathleen Hoeger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- SLC2A9 Is a High-Capacity Urate Transporter in Humans
- (2008) Mark J Caulfield et al. PLOS MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started